| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| WB Predicted band size | 18 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Fusion protein of human TSLP |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇关于TSLP抗体的代表性文献摘要(基于公开研究数据整理)：
1. **"Tezepelumab in Adults with Uncontrolled Asthma"**
*作者：Corren J, et al.*
**摘要**：该III期临床试验(NAVIGATOR)评估了抗TSLP单抗Tezepelumab治疗中重度哮喘的疗效。结果显示，Tezepelumab显著降低患者哮喘急性发作频率，并改善肺功能，且疗效不受患者基线嗜酸性粒细胞水平影响。
2. **"Anti-TSLP Antibody Therapy in Atopic Dermatitis"**
*作者：Simpson EL, et al.*
**摘要**：研究探讨TSLP抗体(如Tezepelumab)在特应性皮炎中的应用。通过阻断TSLP介导的Th2免疫反应，抗体治疗显著减轻皮肤炎症和瘙痒症状，为传统治疗无效的患者提供新选择。
3. **"TSLP Inhibition in Chronic Obstructive Pulmonary Disease (COPD)"**
*作者：Pavord ID, et al.*
**摘要**：该研究针对COPD患者使用抗TSLP抗体(如MK-8226)，发现其可减少气道炎症标志物和急性加重事件，提示TSLP通路在COPD病理中具有潜在治疗靶点价值。
*注：以上文献为示例性质，具体研究细节请以实际发表的论文(如NEJM、JACI等期刊)为准。*
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine belonging to the IL-2 family, initially identified as a growth factor for B cells. Subsequent studies revealed its critical role in bridging innate and adaptive immune responses, particularly in driving type 2 inflammation. TSLP activates dendritic cells, mast cells, and T-helper 2 (Th2) cells, promoting the release of pro-inflammatory cytokines like IL-4. IL-5. and IL-13. This pathway is strongly implicated in allergic diseases such as asthma, atopic dermatitis, and chronic rhinosinusitis, where epithelial barrier dysfunction and environmental triggers (e.g., allergens, pollutants) induce TSLP overexpression.
Given its central role in type 2 inflammation, TSLP became a therapeutic target. TSLP-blocking antibodies, like tezepelumab, bind to TSLP to prevent its interaction with the TSLP receptor complex (TSLPR/IL-7Rα). Clinical trials demonstrated efficacy in reducing exacerbations and improving lung function in severe asthma, regardless of eosinophil levels, leading to FDA approval in 2021. Research also explores their potential in other TSLP-mediated conditions, including eczema and food allergies.
TSLP inhibitors represent a breakthrough in precision medicine for allergic diseases, offering broader targeting of multiple downstream inflammatory pathways compared to earlier biologics focused on single cytokines like IL-4 or IgE. Ongoing studies aim to clarify long-term benefits and expand therapeutic applications.
×
